Form 4: Elicio Therapeutics Director Karen Wilson Reports Stock Option Grant
SEC Form 4 Filing
Director Karen Wilson reports the grant of stock options in Elicio Therapeutics, Inc.
Summary
- Karen Wilson, a director of Elicio Therapeutics, Inc. [ELTX], filed a Form 4 on May 20, 2025.
- The report details the grant of stock options to Wilson on May 19, 2025.
- Wilson was granted options to purchase 7,900 shares of common stock at an exercise price of $5.84 per share.
- The options vest fully on the earlier of May 19, 2026, or the next annual meeting of the company's stockholders after the grant date, contingent on continued service to the issuer.
- Following the transaction, Wilson directly owns 7,900 derivative securities (stock options).
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The grant of stock options is a standard practice and suggests confidence in the company's future performance. There are no explicitly negative aspects in the filing.
Positives
- The grant of stock options to a director aligns their interests with those of the shareholders.
- The vesting schedule incentivizes continued service to the company.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
- The vesting schedule of one year is fairly typical, although some companies may use different vesting periods or performance-based vesting criteria.
- The exercise price is set at the market price on the grant date, which is standard practice.
Stakeholder Impact
- The stock option grant could potentially increase shareholder value if the company performs well and the options become valuable.
Key Dates
| Date | Description |
|---|---|
| 05/19/2025 | Date of stock option grant and transaction. |
| 05/19/2026 | First possible vesting date for the stock options (one-year anniversary of grant date). |
| 05/20/2025 | Date of Form 4 filing. |
| 05/19/2035 | Expiration date of the stock options. |
Keywords
Form 4, Stock Options, Elicio Therapeutics, Director, Beneficial Ownership, ELTX, Karen Wilson
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.